HEALTHJun 4 · 20:18 UTCSTAT NEWSElaine Chen, Adam Feuerstein, and Allison DeAngelis

What RevMed’s pancreatic cancer drug meant for one patient

Revolution Medicines' pancreatic cancer drug, daraxonrasib, received a standing ovation from oncologists during a data presentation. The article also addresses the poor performance of biotech stocks this week and discusses other topics on 'The Readout LOUD' podcast.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Revolution Medicinesorganizationdaraxonrasibtopiconcologistspersonbiotech stockstopicpancreatic cancertopicThe Readout LOUDorganization

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 1 · 13:30 UTC
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
HEALTHJun 1 · 13:12 UTC
STAT+: A turning point for pancreatic cancer patients
HEALTHMay 31 · 12:00 UTC
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
HEALTHJun 4 · 17:15 UTC
STAT+: For pancreatic cancer patients, an exciting drug can feel out of reach
HEALTHJun 4 · 10:30 UTC
STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?
HEALTHMay 1 · 19:14 UTC
FDA expands access to drug helping pancreatic cancer patients